Le Lézard
Classified in: Health
Subjects: CCA, BFA

Abaxis To Report Second Quarter Fiscal Year 2018 Financial Results On Tuesday, October 24, 2017


UNION CITY, Calif., Oct. 17, 2017 /PRNewswire/ -- Abaxis, Inc. (Nasdaq: ABAX), a global diagnostics company manufacturing point-of-care blood analysis instruments and consumables for the medical and veterinary markets worldwide, has scheduled a conference call to discuss its financial results for the second quarter fiscal year 2018, ended September 30, 2017. The call will be at 4:15 p.m. ET on Tuesday, October 24, 2017.  The Company will report financial results for the second quarter fiscal year 2018 after market close on Tuesday, October 24, 2017.

Participants can dial (844) 855-9498 or (412) 317-5496 to access the conference call, or can listen via a live Internet web cast, which is available in the Investor Relations section of the Company's website at www.abaxis.com. A replay of the call is available by visiting www.abaxis.com for the next 30 days or by calling (877) 344-7529 or (412) 317-0088, confirmation code 10113411, through October 31, 2017.

About Abaxis

Abaxis, Inc. is a worldwide developer, manufacturer and marketer of portable blood analysis systems that are used in a broad range of medical specialties in human or veterinary patient care to provide clinicians with rapid blood constituent measurements.  Our mission is to improve the efficiency of care delivery to and the quality of life of patients in the medical and veterinary markets.  We provide leading edge technology and tools that support best medical practices, enabling physicians and veterinarians to respond to the health needs of their clients at the point of care while operating economical and profitable practices.  For more information, visit http://www.abaxis.com

Contact:

Clint Severson

Lytham Partners, LLC


Chief Executive Officer

Joe Dorame, Joe Diaz & Robert Blum


Abaxis, Inc.

602-889-9700


510-675-6500


 

SOURCE Abaxis, Inc.


These press releases may also interest you

at 01:00
PARIS, FRANCE, 24 April 2024 - Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty-care biopharmaceutical company, today presents its sales for the first quarter of 2024. ? ?  Q1 2024? Q1 2023? % change? ?m? ?m? ActualCER1Growth...

23 avr 2024
GenScript, a global leader in life sciences and biotechnology, successfully hosted an Open Day event at its Singapore facility on the 16th of April, welcoming more than 50 representatives from Singapore. This event provided an exclusive look into...

23 avr 2024
Cybervation, an award-winning global technology and healthcare solutions company, proudly announces that its CEO, Purba Majumder, has been distinguished as one of the 2024 100 Women to KNOW Across America. This award from KNOW Women recognizes...

23 avr 2024
The report titled "Glycated Albumin Assay Market by Product (Animal Glycated Albumin Assay, Human Glycated Albumin Assay), Application (Prediabetes, Type 1 Diabetes, Type 2 Diabetes), End User - Global Forecast 2024-2030" is now available on...

23 avr 2024
The report titled "Health & Wellness Food Market by Type (Fresh & Natural, Functional Foods & Beverages, Heat & Eat), Nature (Genetically Modified Organism Food, Non-Genetically Modified Organism Food), Fat Content, Category, Free From Category,...

23 avr 2024
Hanmi Pharmaceutical (KOSPI: 128940, CEO: Jae-Hyun Park), a leading biopharma company in Korea that focuses on research areas such as oncology, obesity/metabolism, and rare diseases, announced it has entered into a Clinical Trial Collaboration and...



News published on and distributed by: